Recently, a computer tomography (CT) signature consisting of 12 CT features in stage IV EGFR-mutant NSCLC patients with EGFR-TKI therapy, demonstrated good accuracy for discriminating patients with rapid and slow progression to EGFR-TKI therapy (31). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.